EFFECTS OF ACETYLSALICYLIC ACID AND CLOPIDOGREL ON MORPHOFUNCTIONAL STATUS OF ERYTHROCYTES IN PATIENTS WITH ACUTE CORONARY SYNDROME
https://doi.org/10.20996/1819-6446-2009-5-5-46-52
Abstract
Aim. In patients with acute coronary syndrome (ACS) to study an aggregation activity and morphology of erythrocytes and to assess their changes during therapy with acetylsalicylic acid, clopidogrel and combined antiplatelet therapy (acetylsalicylic acid and clopidogrel).
Material and methods. 98 patients (67 men and 31 women, aged 59,6±10,8 y.o.) with ACS were included in the study. Patients were split in 3 groups depending on prescribed antiplatelets (acetylsalicylic acid; clopidogrel; acetylsalicylic acid+clopidogrel). Aggregation activity and morphofunctional status of erythrocytes were evaluated at baseline, after 3 and 7 days of treatment.
Results. The highest efficacy of antiaggregant therapy was observed in patients receiving antiplatelet combination. In this group there was a maximal reduction of erythrocyte aggregation and a number of pathological erythrocytes in peripheral blood by the 3rd day of therapy. This effect was increasing by the 7th day.
Conclusion. The effect of all antiplatelet drugs was significant. The antiaggregant effect of clopidogrel was more significant than this for acetylsalicylic acid. Efficacy of combined therapy was higher than these for each drug alone.
About the Authors
A. L. Alyavi
Republic Research Center for Urgent Medical Care
Uzbekistan
Farhadskaya ul. 2, Chilansarskiy rayon, Tashkent 100071
Uzbekistan
Farhadskaya ul. 2, Chilansarskiy rayon, Tashkent 100071
R. A. Rakhimov
Republic Research Center for Urgent Medical Care
Uzbekistan
Farhadskaya ul. 2, Chilansarskiy rayon, Tashkent 100071
Uzbekistan
Farhadskaya ul. 2, Chilansarskiy rayon, Tashkent 100071
B. A. Alyavi
Republic Research Center for Urgent Medical Care
Uzbekistan
Farhadskaya ul. 2, Chilansarskiy rayon, Tashkent 100071
Uzbekistan
Farhadskaya ul. 2, Chilansarskiy rayon, Tashkent 100071
References
1. Andrews N.P., Husain M., Dakak N., Quyyumi A.A. Platelet inhibitory effect of nitric oxide in the human coronary circulation: impact of endothelial dysfunction. J Am Coll Cardiol 2001;37(2):510-6.
2. Blann A. Antiplatelet therapy and the vascular tree. Heart 2006;92(1): 3-4.
3. Fuster V., Badimon L., Badimon J.J., Chesebro J.H. The pathogenesis of coronary artery disease and the acute coronary syndromes (1). N Engl J Med 1992;326(4):242-50.
4. Fuster V., Badimon L., Badimon J.J., Chesebro J.H. The pathogenesis of coronary artery disease and the acute coronary syndromes (2). N Engl J Med 1992;326(5):310-8.
5. Kristensen S.D., Lassen J.F., Ravn H.B. Pathophysiology of coronary thrombosis. Semin Interv Cardiol 2000;5(3):109-15.
6. Бокарев И.Н., Аксенова М.Б., Хлевчук Т.В. Острый коронарный синдром и его лечение. М.: УРАО; 2001.
7. Björklund E., Stenestrand U., Lindbäck J. et al. Pre-hospital thrombolysis delivered by paramedics is associated with reduced time delay and mortality in ambulance-transported real-life patients with ST-elevation myocardial infarction. Eur Heart J 2006;27(10):1146–52.
8. Blazing M.A., De Lemos J.A., Dyke C.K. et al. The A-to-Z Trial: Methods and rationale for a single trial investigating combined use of lowmolecular-weight heparin with the glycoprotein IIb/IIIa inhibitor tirofiban and defining the efficacy of early aggressive simvastatin therapy. Am Heart J 2001;142(2):211–7.
9. Goodman S.G., Fitchett D., Armstrong P.W. et al. Randomized evaluation of the safety and efficacy of enoxaparin versus unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes receiving the glycoprotein IIb/IIIa inhibitor eptifibatide. Circulation 2003;107(2):238–44.
10. Long-term low-molecular-mass heparin in unstable coronary-artery disease: FRISC II prospective randomised multicentre study. FRagmin and Fast Revascularisation during InStability in Coronary artery disease. Investigators. Lancet 1999;354(9180):701–7.
11. Бокарев И.Н., Щепотин В.М., Ена Я.М. Внутрисосудистое свертывание крови. К.: Здоровье; 1989.
12. Кукес В.Г., Остроумова О.Д. Кардиомагнил. Новый взгляд на ацетилсалициловую кислоту. Пособие для врачей. М.; 2004.
13. Vane J.R., Flower R.J., Botting R.M. History of aspirin and its mechanism of action. Stroke 1990;21(12 Suppl):IV12-23.
14. Michelson A.D., Cattaneo M., Eikelboom J.W. et al. Aspirin resistance: position paper of the Working Group on Aspirin Resistance. J Thromb Haemost 2005;3(6):1309-11.
15. Patrono C. Aspirin resistance definition, mechanisms and clinical read-outs. J Thromb Hemost 2003;1(8):1710-3.
16. Остроумова О.Д. Ацетилсалициловая кислота — препарат номер один для лечения сердечно–сосудистых заболеваний. Основные показания к применению, клинические преимущества, эффективные дозы и пути повышения переносимости. РМЖ 2003;11(5):253–5.
17. Patrono C., Coller B., Dalen J.E. et al. Plate-Active Drugs: The relationship among dose, effectiveness and side effects. Chest 2001;119 (1 Suppl):39S–63S.
18. Falk E. Plaque rupture with severe pre-existing stenosis precipitating coronary thrombosis. Characteristics of coronary atherosclerotic plaques underlying fatal occlusive thrombi. Br Heart J 1983;50(2):127-34.
19. Ambrose J.A., Weinrauch M. Thrombosis in ischemic heart disease. Arch Intern Med 1996;156(13):1382-94.
20. Davies M.J., Thomas A.C., Knapman P.A., Hangartner J.R. Intramyocardial platelet aggregation in patients with unstable angina suffering sudden ischemic cardiac death. Circulation 1986;73(3):418-27.
21. Vane J.R. Inhibition of prostaglandin synthesis as a mechanism of action of aspirin-like drugs. Nat New Biol 1971;231(25):232-5.
22. Jarvis B., Simpson K. Clopidogrel: a review of its use in the prevention of atherothrombosis. Drugs 2000;60(2):347-77.
23. Yusuf S., Lessem J., Jha P., Lonn E. Primary and secondary prevention of myocardial infarction and strokes: an update of randomly allocated, controlled trials. J Hypertens Suppl 1993;11(4):S61-73.
Review
For citations:
Alyavi A.L., Rakhimov R.A., Alyavi B.A. EFFECTS OF ACETYLSALICYLIC ACID AND CLOPIDOGREL ON MORPHOFUNCTIONAL STATUS OF ERYTHROCYTES IN PATIENTS WITH ACUTE CORONARY SYNDROME. Rational Pharmacotherapy in Cardiology. 2009;5(5):46-52. (In Russ.) https://doi.org/10.20996/1819-6446-2009-5-5-46-52
Views:
687
.jpg)
Email this article 